Global Human Papillomavirus Testing Market

Human Papillomavirus Testing Comprehensive Study by Type (Primary Testing, Follow-up Testing, Co-Testing), Application (Immunoassays, Monoclonal and Polyclonal Antibodies, Microarrays, Molecular Diagnostics, Chromosome Analysis, Flow Cytometry, Artificial Intelligence, Microcomputers, Biosensors), End User (Laboratories, Hospitals, Physician’s Offices & Clinics) Players and Region - Global Market Outlook to 2030

Human Papillomavirus Testing Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 10.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Human Papillomavirus Testing Market Scope
Human papillomavirus is a kind of virus that is common in the reproductive tract among women and men. The virus is also responsible for cervical cancer, which stands at fourth number among women. The infection transmits during the interval of intercourse and common in those who are sexually active. The testing of the virus through various methods/devices available in the market at several centers such as hospitals and laboratories, defined as the papillomavirus testing market. increasing awareness about the link between the human papillomavirus and cervical cancer coupled with the unmet need for accuracy in diagnostic testing. Failure of human papillomavirus detection by primary screening tests due to less sensitivity and false-negative results makes a positive impact on the market for human papillomavirus testing.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledAbbott Laboratories (United States), Hologic Inc. (United States), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Quest Diagnostics (United States), OncoHealth Corporation (United States), Becton, Dickinson and Company (United States), Roche Diagnostics (Switzerland), Femasys Inc. (United States), Arbor Vita Corporation (United States) and Fujirebio (United States)
CAGR10.3%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Human Papillomavirus Testing market throughout the predicted period.

Abbott Laboratories (United States), Hologic Inc. (United States), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Quest Diagnostics (United States), OncoHealth Corporation (United States), Becton, Dickinson and Company (United States), Roche Diagnostics (Switzerland), Femasys Inc. (United States), Arbor Vita Corporation (United States) and Fujirebio (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are bioMérieux SA (France), Seegene, Inc. (South Korea) and Guided Therapeutics (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Human Papillomavirus Testing market by Type , by Application (Immunoassays, Monoclonal and Polyclonal Antibodies, Microarrays, Molecular Diagnostics, Chromosome Analysis, Flow Cytometry, Artificial Intelligence, Microcomputers and Biosensors) and Region with country level break-up.

On the basis of geography, the market of Human Papillomavirus Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In January 2023, the Serum Institute of India announced the launch of CERVAVAC, India's first indigenously developed quadrivalent HPV vaccine.
"In August 2020, the World Health Organization passed a goal calling for the end of cervical malignant growth and embracing a methodology to get it going. It is a demonstration of the energy for this significant objective that, even with regards to the COVID-19 pandemic, nations around the globe have insisted on their help for this significant need.
American cancer society updates guidelines for cervical cancer screening. The updated guideline recommends that individuals with a cervix initiate cervical cancer screening at age 25 and that primary human papillomavirus (HPV) testing (HPV testing without the Pap test) every 5 years be the preferred method of testing through age 65.

Influencing Trend:
Rising Healthcare Spending in Developing Economies

Market Growth Drivers:
Increasing Number of Cervical Cancer Cases and Growing Aging Population, Increasing Awareness of Cervical Cancer Screening Programs and Government Initiatives and Funding

Challenges:
Uncertain Reimbursement Scenario

Restraints:
Changes in Regulatory Guidelines for Cervical Cancer Screening and Human Papillomavirus Vaccination

Opportunities:
Increasing Prevalence of Cervical Cancer

Key Target Audience
Human Papillomavirus Testing Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

Report Objectives / Segmentation Covered

By Type
  • Primary Testing
  • Follow-up Testing
  • Co-Testing
By Application
  • Immunoassays
  • Monoclonal and Polyclonal Antibodies
  • Microarrays
  • Molecular Diagnostics
  • Chromosome Analysis
  • Flow Cytometry
  • Artificial Intelligence
  • Microcomputers
  • Biosensors
By End User
  • Laboratories
  • Hospitals
  • Physician’s Offices & Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Cervical Cancer Cases and Growing Aging Population
      • 3.2.2. Increasing Awareness of Cervical Cancer Screening Programs
      • 3.2.3. Government Initiatives and Funding
    • 3.3. Market Challenges
      • 3.3.1. Uncertain Reimbursement Scenario
    • 3.4. Market Trends
      • 3.4.1. Rising Healthcare Spending in Developing Economies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Human Papillomavirus Testing, by Type, Application, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Human Papillomavirus Testing (Value)
      • 5.2.1. Global Human Papillomavirus Testing by: Type (Value)
        • 5.2.1.1. Primary Testing
        • 5.2.1.2. Follow-up Testing
        • 5.2.1.3. Co-Testing
      • 5.2.2. Global Human Papillomavirus Testing by: Application (Value)
        • 5.2.2.1. Immunoassays
        • 5.2.2.2. Monoclonal and Polyclonal Antibodies
        • 5.2.2.3. Microarrays
        • 5.2.2.4. Molecular Diagnostics
        • 5.2.2.5. Chromosome Analysis
        • 5.2.2.6. Flow Cytometry
        • 5.2.2.7. Artificial Intelligence
        • 5.2.2.8. Microcomputers
        • 5.2.2.9. Biosensors
      • 5.2.3. Global Human Papillomavirus Testing by: End User (Value)
        • 5.2.3.1. Laboratories
        • 5.2.3.2. Hospitals
        • 5.2.3.3. Physician’s Offices & Clinics
      • 5.2.4. Global Human Papillomavirus Testing Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Human Papillomavirus Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Hologic Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Qiagen N.V. (Netherlands)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Quest Diagnostics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. OncoHealth Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Becton, Dickinson and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Roche Diagnostics (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Femasys Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Arbor Vita Corporation (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Fujirebio (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Human Papillomavirus Testing Sale, by Type, Application, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Human Papillomavirus Testing (Value)
      • 7.2.1. Global Human Papillomavirus Testing by: Type (Value)
        • 7.2.1.1. Primary Testing
        • 7.2.1.2. Follow-up Testing
        • 7.2.1.3. Co-Testing
      • 7.2.2. Global Human Papillomavirus Testing by: Application (Value)
        • 7.2.2.1. Immunoassays
        • 7.2.2.2. Monoclonal and Polyclonal Antibodies
        • 7.2.2.3. Microarrays
        • 7.2.2.4. Molecular Diagnostics
        • 7.2.2.5. Chromosome Analysis
        • 7.2.2.6. Flow Cytometry
        • 7.2.2.7. Artificial Intelligence
        • 7.2.2.8. Microcomputers
        • 7.2.2.9. Biosensors
      • 7.2.3. Global Human Papillomavirus Testing by: End User (Value)
        • 7.2.3.1. Laboratories
        • 7.2.3.2. Hospitals
        • 7.2.3.3. Physician’s Offices & Clinics
      • 7.2.4. Global Human Papillomavirus Testing Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Human Papillomavirus Testing: by Type(USD Million)
  • Table 2. Human Papillomavirus Testing Primary Testing , by Region USD Million (2018-2023)
  • Table 3. Human Papillomavirus Testing Follow-up Testing , by Region USD Million (2018-2023)
  • Table 4. Human Papillomavirus Testing Co-Testing , by Region USD Million (2018-2023)
  • Table 5. Human Papillomavirus Testing: by Application(USD Million)
  • Table 6. Human Papillomavirus Testing Immunoassays , by Region USD Million (2018-2023)
  • Table 7. Human Papillomavirus Testing Monoclonal and Polyclonal Antibodies , by Region USD Million (2018-2023)
  • Table 8. Human Papillomavirus Testing Microarrays , by Region USD Million (2018-2023)
  • Table 9. Human Papillomavirus Testing Molecular Diagnostics , by Region USD Million (2018-2023)
  • Table 10. Human Papillomavirus Testing Chromosome Analysis , by Region USD Million (2018-2023)
  • Table 11. Human Papillomavirus Testing Flow Cytometry , by Region USD Million (2018-2023)
  • Table 12. Human Papillomavirus Testing Artificial Intelligence , by Region USD Million (2018-2023)
  • Table 13. Human Papillomavirus Testing Microcomputers , by Region USD Million (2018-2023)
  • Table 14. Human Papillomavirus Testing Biosensors , by Region USD Million (2018-2023)
  • Table 15. Human Papillomavirus Testing: by End User(USD Million)
  • Table 16. Human Papillomavirus Testing Laboratories , by Region USD Million (2018-2023)
  • Table 17. Human Papillomavirus Testing Hospitals , by Region USD Million (2018-2023)
  • Table 18. Human Papillomavirus Testing Physician’s Offices & Clinics , by Region USD Million (2018-2023)
  • Table 19. South America Human Papillomavirus Testing, by Country USD Million (2018-2023)
  • Table 20. South America Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 21. South America Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 22. South America Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 23. Brazil Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 24. Brazil Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 25. Brazil Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 26. Argentina Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 27. Argentina Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 28. Argentina Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 29. Rest of South America Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 30. Rest of South America Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 31. Rest of South America Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 32. Asia Pacific Human Papillomavirus Testing, by Country USD Million (2018-2023)
  • Table 33. Asia Pacific Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 34. Asia Pacific Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 35. Asia Pacific Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 36. China Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 37. China Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 38. China Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 39. Japan Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 40. Japan Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 41. Japan Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 42. India Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 43. India Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 44. India Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 45. South Korea Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 46. South Korea Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 47. South Korea Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 48. Taiwan Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 49. Taiwan Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 50. Taiwan Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 51. Australia Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 52. Australia Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 53. Australia Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 55. Rest of Asia-Pacific Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 56. Rest of Asia-Pacific Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 57. Europe Human Papillomavirus Testing, by Country USD Million (2018-2023)
  • Table 58. Europe Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 59. Europe Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 60. Europe Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 61. Germany Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 62. Germany Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 63. Germany Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 64. France Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 65. France Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 66. France Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 67. Italy Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 68. Italy Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 69. Italy Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 70. United Kingdom Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 71. United Kingdom Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 72. United Kingdom Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 73. Netherlands Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 74. Netherlands Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 75. Netherlands Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 76. Rest of Europe Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 77. Rest of Europe Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 78. Rest of Europe Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 79. MEA Human Papillomavirus Testing, by Country USD Million (2018-2023)
  • Table 80. MEA Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 81. MEA Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 82. MEA Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 83. Middle East Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 84. Middle East Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 85. Middle East Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 86. Africa Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 87. Africa Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 88. Africa Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 89. North America Human Papillomavirus Testing, by Country USD Million (2018-2023)
  • Table 90. North America Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 91. North America Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 92. North America Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 93. United States Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 94. United States Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 95. United States Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 96. Canada Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 97. Canada Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 98. Canada Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 99. Mexico Human Papillomavirus Testing, by Type USD Million (2018-2023)
  • Table 100. Mexico Human Papillomavirus Testing, by Application USD Million (2018-2023)
  • Table 101. Mexico Human Papillomavirus Testing, by End User USD Million (2018-2023)
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Human Papillomavirus Testing: by Type(USD Million)
  • Table 114. Human Papillomavirus Testing Primary Testing , by Region USD Million (2025-2030)
  • Table 115. Human Papillomavirus Testing Follow-up Testing , by Region USD Million (2025-2030)
  • Table 116. Human Papillomavirus Testing Co-Testing , by Region USD Million (2025-2030)
  • Table 117. Human Papillomavirus Testing: by Application(USD Million)
  • Table 118. Human Papillomavirus Testing Immunoassays , by Region USD Million (2025-2030)
  • Table 119. Human Papillomavirus Testing Monoclonal and Polyclonal Antibodies , by Region USD Million (2025-2030)
  • Table 120. Human Papillomavirus Testing Microarrays , by Region USD Million (2025-2030)
  • Table 121. Human Papillomavirus Testing Molecular Diagnostics , by Region USD Million (2025-2030)
  • Table 122. Human Papillomavirus Testing Chromosome Analysis , by Region USD Million (2025-2030)
  • Table 123. Human Papillomavirus Testing Flow Cytometry , by Region USD Million (2025-2030)
  • Table 124. Human Papillomavirus Testing Artificial Intelligence , by Region USD Million (2025-2030)
  • Table 125. Human Papillomavirus Testing Microcomputers , by Region USD Million (2025-2030)
  • Table 126. Human Papillomavirus Testing Biosensors , by Region USD Million (2025-2030)
  • Table 127. Human Papillomavirus Testing: by End User(USD Million)
  • Table 128. Human Papillomavirus Testing Laboratories , by Region USD Million (2025-2030)
  • Table 129. Human Papillomavirus Testing Hospitals , by Region USD Million (2025-2030)
  • Table 130. Human Papillomavirus Testing Physician’s Offices & Clinics , by Region USD Million (2025-2030)
  • Table 131. South America Human Papillomavirus Testing, by Country USD Million (2025-2030)
  • Table 132. South America Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 133. South America Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 134. South America Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 135. Brazil Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 136. Brazil Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 137. Brazil Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 138. Argentina Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 139. Argentina Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 140. Argentina Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 141. Rest of South America Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 142. Rest of South America Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 143. Rest of South America Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 144. Asia Pacific Human Papillomavirus Testing, by Country USD Million (2025-2030)
  • Table 145. Asia Pacific Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 146. Asia Pacific Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 147. Asia Pacific Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 148. China Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 149. China Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 150. China Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 151. Japan Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 152. Japan Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 153. Japan Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 154. India Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 155. India Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 156. India Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 157. South Korea Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 158. South Korea Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 159. South Korea Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 160. Taiwan Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 161. Taiwan Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 162. Taiwan Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 163. Australia Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 164. Australia Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 165. Australia Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 166. Rest of Asia-Pacific Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 167. Rest of Asia-Pacific Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 168. Rest of Asia-Pacific Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 169. Europe Human Papillomavirus Testing, by Country USD Million (2025-2030)
  • Table 170. Europe Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 171. Europe Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 172. Europe Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 173. Germany Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 174. Germany Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 175. Germany Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 176. France Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 177. France Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 178. France Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 179. Italy Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 180. Italy Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 181. Italy Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 182. United Kingdom Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 183. United Kingdom Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 184. United Kingdom Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 185. Netherlands Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 186. Netherlands Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 187. Netherlands Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 188. Rest of Europe Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 189. Rest of Europe Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 190. Rest of Europe Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 191. MEA Human Papillomavirus Testing, by Country USD Million (2025-2030)
  • Table 192. MEA Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 193. MEA Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 194. MEA Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 195. Middle East Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 196. Middle East Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 197. Middle East Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 198. Africa Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 199. Africa Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 200. Africa Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 201. North America Human Papillomavirus Testing, by Country USD Million (2025-2030)
  • Table 202. North America Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 203. North America Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 204. North America Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 205. United States Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 206. United States Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 207. United States Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 208. Canada Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 209. Canada Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 210. Canada Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 211. Mexico Human Papillomavirus Testing, by Type USD Million (2025-2030)
  • Table 212. Mexico Human Papillomavirus Testing, by Application USD Million (2025-2030)
  • Table 213. Mexico Human Papillomavirus Testing, by End User USD Million (2025-2030)
  • Table 214. Research Programs/Design for This Report
  • Table 215. Key Data Information from Secondary Sources
  • Table 216. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Human Papillomavirus Testing: by Type USD Million (2018-2023)
  • Figure 5. Global Human Papillomavirus Testing: by Application USD Million (2018-2023)
  • Figure 6. Global Human Papillomavirus Testing: by End User USD Million (2018-2023)
  • Figure 7. South America Human Papillomavirus Testing Share (%), by Country
  • Figure 8. Asia Pacific Human Papillomavirus Testing Share (%), by Country
  • Figure 9. Europe Human Papillomavirus Testing Share (%), by Country
  • Figure 10. MEA Human Papillomavirus Testing Share (%), by Country
  • Figure 11. North America Human Papillomavirus Testing Share (%), by Country
  • Figure 12. Global Human Papillomavirus Testing share by Players 2023 (%)
  • Figure 13. Global Human Papillomavirus Testing share by Players (Top 3) 2023(%)
  • Figure 14. Global Human Papillomavirus Testing share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 17. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 18. Hologic Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Hologic Inc. (United States) Revenue: by Geography 2023
  • Figure 20. Qiagen N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 21. Qiagen N.V. (Netherlands) Revenue: by Geography 2023
  • Figure 22. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 24. Quest Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 25. Quest Diagnostics (United States) Revenue: by Geography 2023
  • Figure 26. OncoHealth Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. OncoHealth Corporation (United States) Revenue: by Geography 2023
  • Figure 28. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 29. Becton, Dickinson and Company (United States) Revenue: by Geography 2023
  • Figure 30. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Roche Diagnostics (Switzerland) Revenue: by Geography 2023
  • Figure 32. Femasys Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Femasys Inc. (United States) Revenue: by Geography 2023
  • Figure 34. Arbor Vita Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 35. Arbor Vita Corporation (United States) Revenue: by Geography 2023
  • Figure 36. Fujirebio (United States) Revenue, Net Income and Gross profit
  • Figure 37. Fujirebio (United States) Revenue: by Geography 2023
  • Figure 38. Global Human Papillomavirus Testing: by Type USD Million (2025-2030)
  • Figure 39. Global Human Papillomavirus Testing: by Application USD Million (2025-2030)
  • Figure 40. Global Human Papillomavirus Testing: by End User USD Million (2025-2030)
  • Figure 41. South America Human Papillomavirus Testing Share (%), by Country
  • Figure 42. Asia Pacific Human Papillomavirus Testing Share (%), by Country
  • Figure 43. Europe Human Papillomavirus Testing Share (%), by Country
  • Figure 44. MEA Human Papillomavirus Testing Share (%), by Country
  • Figure 45. North America Human Papillomavirus Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Hologic Inc. (United States)
  • Qiagen N.V. (Netherlands)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Quest Diagnostics (United States)
  • OncoHealth Corporation (United States)
  • Becton, Dickinson and Company (United States)
  • Roche Diagnostics (Switzerland)
  • Femasys Inc. (United States)
  • Arbor Vita Corporation (United States)
  • Fujirebio (United States)
Additional players considered in the study are as follows:
bioMérieux SA (France) , Seegene, Inc. (South Korea) , Guided Therapeutics (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 215 Pages 83 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Human Papillomavirus Testing Market Quantitative research analysis
Global Human Papillomavirus Testing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Human Papillomavirus Testing Market are by type [Primary Testing, Follow-up Testing and Co-Testing], by end use application [Immunoassays, Monoclonal and Polyclonal Antibodies, Microarrays, Molecular Diagnostics, Chromosome Analysis, Flow Cytometry, Artificial Intelligence, Microcomputers and Biosensors].
The Human Papillomavirus Testing Market is gaining popularity and expected to see strong valuation by 2030.
  • Increasing Number of Cervical Cancer Cases and Growing Aging Population
  • Increasing Awareness of Cervical Cancer Screening Programs
  • Government Initiatives and Funding

Know More About Global Human Papillomavirus Testing Market Report?

Have a Query? Click Here

Other Related Reports

Paramedic Services Comprehensive Study by Type (Emergency Paramedic Services, General Paramedic Services), Application (Pre-hospital Support, Post-hospital Support), Service Level (Basic Life Support...
$ 3750
Bovine Mastitis  Comprehensive Study by Therapy (Lactating Period, Dry Period {Antibiotics, Others}), Mastitis (Clinical mastitis, Sub-Clinical mastitis, Peracute mastitis, Acute mastitis, Subacute ...
$ 3750
Histopathology Services Comprehensive Study by Examination (Surgical Specimen, Breast Biopsy, Gastrointestinal Biopsy, Testicular Biopsy, Lung Biopsy, Renal Biopsy, Biopsy of Gynecological Cancers, L...
$ 3750
Vaccine Storage & Packaging Comprehensive Study by Type (Vaccine Storage, Vaccine Packaging), Vaccine Packaging (Packaging (Vaccine Cool Bags, Vials, and Ampoules, Corrugated Boxes, Others), Packagin...
$ 3750
Animal Treatment Comprehensive Study by Type (Pharmaceuticals, Feed Additives), Application (Laboratory Services, Animal Emergency Care, Pain Management, Animal Specialty Services, Vitamins and Suppl...
$ 3650
Lymphedema Diagnostics Comprehensive Study by Application (Lymphedema Surgery Center, Hospitals, Clinics), Diagnostic Tests (MRI Scan, CT Scan, Doppler Ultrasound, Lymphoscintigraphy), Disease Type (...
$ 3750